Does the media favor HALO or RVMD?

In the previous week, Revolution Medicines had 8 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 14 mentions for Revolution Medicines and 6 mentions for Halozyme Therapeutics. Revolution Medicines' average media sentiment score of 0.57 beat Halozyme Therapeutics' score of 0.19 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or ALNY?

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 6 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.19 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BIIB or HALO?

In the previous week, Biogen had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 9 mentions for Biogen and 6 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.02 beat Halozyme Therapeutics' score of 0.19 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ROIV or HALO?

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 3 mentions for Roivant Sciences. Halozyme Therapeutics' average media sentiment score of 0.19 beat Roivant Sciences' score of -0.54 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HALO or INSM?

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Insmed. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 4 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Halozyme Therapeutics' score of 0.19 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Halozyme Therapeutics (HALO) Competitors

$109.86 +2.92 (+2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$109.86 +0.00 (+0.00%)

As of 07:30 PM Eastern

Compare

HALO vs. RVMD, ALNY, BIIB, ROIV, and INSM

Should you buy Halozyme Therapeutics stock or one of its competitors? Halozyme Therapeutics's main competitors and comparable companies include Revolution Medicines (RVMD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Halozyme Therapeutics compare to Revolution Medicines?

Halozyme Therapeutics (NASDAQ:HALO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Halozyme Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.85	$316.89M	$3.35	32.51
Revolution Medicines	$11.58M	3,832.60	-$1.13B	-$8.82	N/A

Halozyme Therapeutics has a net margin of 24.86% compared to Revolution Medicines' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Revolution Medicines	N/A	-88.20%	-57.85%

Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Halozyme Therapeutics presently has a consensus price target of $91.20, indicating a potential downside of 16.25%. Revolution Medicines has a consensus price target of $234.33, indicating a potential upside of 13.17%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96

In the previous week, Revolution Medicines had 8 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 14 mentions for Revolution Medicines and 6 mentions for Halozyme Therapeutics. Revolution Medicines' average media sentiment score of 0.57 beat Halozyme Therapeutics' score of 0.19 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Halozyme Therapeutics (NASDAQ:HALO) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Halozyme Therapeutics presently has a consensus price target of $91.20, indicating a potential downside of 16.25%. Alnylam Pharmaceuticals has a consensus price target of $366.90, indicating a potential upside of 65.23%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 24.86% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Halozyme Therapeutics' return on equity of 260.98% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 6 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.19 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Halozyme Therapeutics has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.85	$316.89M	$3.35	32.51
Alnylam Pharmaceuticals	$3.71B	8.00	$313.75M	$5.38	41.27

Summary

Halozyme Therapeutics beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Halozyme Therapeutics has a net margin of 24.86% compared to Biogen's net margin of 8.32%. Halozyme Therapeutics' return on equity of 260.98% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Biogen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.30	$1.29B	$5.65	39.06
Halozyme Therapeutics	$1.40B	8.85	$316.89M	$3.35	32.51

Biogen has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Biogen currently has a consensus price target of $230.14, suggesting a potential upside of 4.30%. Halozyme Therapeutics has a consensus price target of $91.20, suggesting a potential downside of 16.25%. Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

In the previous week, Biogen had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 9 mentions for Biogen and 6 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.02 beat Halozyme Therapeutics' score of 0.19 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biogen beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Halozyme Therapeutics has a net margin of 24.86% compared to Roivant Sciences' net margin of -3,534.96%. Halozyme Therapeutics' return on equity of 260.98% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Halozyme Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,120.49	-$299.77M	-$0.53	N/A
Halozyme Therapeutics	$1.40B	8.85	$316.89M	$3.35	32.51

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 3 mentions for Roivant Sciences. Halozyme Therapeutics' average media sentiment score of 0.19 beat Roivant Sciences' score of -0.54 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences currently has a consensus price target of $45.64, indicating a potential upside of 27.89%. Halozyme Therapeutics has a consensus price target of $91.20, indicating a potential downside of 16.25%. Given Roivant Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Roivant Sciences is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Roivant Sciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Insmed?

Halozyme Therapeutics (NASDAQ:HALO) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Halozyme Therapeutics currently has a consensus target price of $91.20, suggesting a potential downside of 16.25%. Insmed has a consensus target price of $200.57, suggesting a potential upside of 84.31%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Halozyme Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to Insmed's net margin of -76.94%. Halozyme Therapeutics' return on equity of 260.98% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Insmed	-76.94%	-123.94%	-44.30%

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Insmed. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 4 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Halozyme Therapeutics' score of 0.19 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.85	$316.89M	$3.35	32.51
Insmed	$606.42M	39.19	-$1.28B	-$4.11	N/A

Summary

Halozyme Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HALO vs. The Competition

Export

Metric	Halozyme Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.47B	$3.84B	$7.09B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	32.79	12.99	274.61	26.05
Price / Sales	8.93	1,288.54	600.52	89.39
Price / Cash	23.14	121.76	77.38	51.25
Price / Book	261.57	16.63	10.92	6.31
Net Income	$316.89M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-3.55%	-3.05%	-2.11%	-1.67%
1 Month Performance	0.18%	-10.75%	-6.34%	-3.94%
1 Year Performance	53.24%	21.11%	8.81%	2.77%

Halozyme Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HALO Halozyme Therapeutics	2.7512 of 5 stars	$109.86 +2.7%	$91.20 -17.0%	+42.7%	$12.47B	$1.40B	32.79	423	Insider Trade
RVMD Revolution Medicines	3.0481 of 5 stars	$192.76 +0.9%	$228.21 +18.4%	+349.0%	$40.93B	$11.58M	N/A	883	Insider Trade Analyst Revision
ALNY Alnylam Pharmaceuticals	3.9166 of 5 stars	$244.32 +2.0%	$367.20 +50.3%	-49.8%	$32.06B	$3.71B	45.41	2,770	Analyst Forecast
BIIB Biogen	3.0438 of 5 stars	$219.07 +1.7%	$230.14 +5.1%	+44.5%	$31.84B	$9.89B	38.77	7,500	Trending News
ROIV Roivant Sciences	2.6295 of 5 stars	$38.99 -2.0%	$45.64 +17.0%	+125.4%	$28.73B	$8.26M	N/A	721

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HALO) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Competitors

HALO vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does Halozyme Therapeutics compare to Revolution Medicines?

Summary

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Halozyme Therapeutics compare to Biogen?

Summary

How does Halozyme Therapeutics compare to Roivant Sciences?

Summary

How does Halozyme Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Competitors

HALO vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does Halozyme Therapeutics compare to Revolution Medicines?

Do insiders & institutionals believe in HALO or RVMD?

Which has stronger earnings & valuation, HALO or RVMD?

Is HALO or RVMD more profitable?

Which has more risk and volatility, HALO or RVMD?

Do analysts rate HALO or RVMD?

Does the media favor HALO or RVMD?

Summary

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Which has more volatility and risk, HALO or ALNY?

Do analysts prefer HALO or ALNY?

Do institutionals & insiders hold more shares of HALO or ALNY?

Is HALO or ALNY more profitable?

Does the media favor HALO or ALNY?

Which has higher earnings & valuation, HALO or ALNY?

Summary

How does Halozyme Therapeutics compare to Biogen?

Is BIIB or HALO more profitable?

Which has stronger earnings and valuation, BIIB or HALO?

Which has more volatility and risk, BIIB or HALO?

Do analysts recommend BIIB or HALO?

Does the media refer more to BIIB or HALO?

Do institutionals and insiders have more ownership in BIIB or HALO?

Summary

How does Halozyme Therapeutics compare to Roivant Sciences?

Is ROIV or HALO more profitable?

Which has preferable valuation & earnings, ROIV or HALO?

Do institutionals and insiders believe in ROIV or HALO?

Does the media refer more to ROIV or HALO?

Do analysts rate ROIV or HALO?

Which has more volatility and risk, ROIV or HALO?

Summary

How does Halozyme Therapeutics compare to Insmed?

Do insiders and institutionals hold more shares of HALO or INSM?

Do analysts prefer HALO or INSM?

Which has more risk and volatility, HALO or INSM?

Is HALO or INSM more profitable?

Does the media refer more to HALO or INSM?

Which has higher valuation and earnings, HALO or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools